Efficient B Cell Depletion via Diphtheria Toxin in CD19-Cre/iDTR Mice

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Demircik, Filiz ^a   Buch, Thorsten ^b   Waisman, Ari ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CRE RECOMBINASE; DIPHTHERIA TOXIN; IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELL COUNT; CONTROLLED STUDY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE SUBPOPULATION; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMA CELL;

ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTES; BACTERIAL PROTEINS; DIPHTHERIA TOXIN; IMMUNOGLOBULINS; INTEGRASES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUMINESCENT PROTEINS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLASMA CELLS; SYNDECAN-1;

MUS;

EID: 84875431323     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060643     Document Type: Article

References (30)

1. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, et al. (2011) Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543-1550.
2. Cerny A, Kimoto M, Hugin AW, Merino R, Izui S, (1989) Anti-IgM treatment of C57BL/6-1pr/1pr mice: depletion of B cells reduces 1pr gene-induced lymphoproliferation and mononuclear cell vasculitis. Clin Exp Immunol 77: 124-129.
3. Rayfield LS, Smith TA, Andrews SJ, Bergmeier LA, (1989) Induction of experimental autoimmune thyroiditis in B cell-depleted mice. Immunol Lett 20: 21-27.
4. Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, et al. (2011) TLR7-driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity. Blood.
5. Zocher M, Baeuerle PA, Dreier T, Iglesias A, (2003) Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. Int Immunol 15: 789-796.
6. Barun B, Bar-Or A (2011) Treatment of multiple sclerosis with Anti-CD20 antibodies. Clin Immunol.
7. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688.
8. Townsend MJ, Monroe JG, Chan AC, (2010) B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 237: 264-283.
9. Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, et al. (2010) B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 68: 369-383.
10. Hagemeister F, (2010) Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70: 261-272.
11. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, et al. (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111: 5486-5495.
12. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
13. Scheuermann RH, Racila E, (1995) CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 18: 385-397.
14. Slaper-Cortenbach IC, Admiraal LG, van Leeuwen EF, Kerr JM, von dem Borne AE, et al. (1990) Effective purging of bone marrow by a combination of immunorosette depletion and complement lysis. Exp Hematol 18: 49-54.
15. Winter JN, Marder RJ, Radosevich JA, Epstein AL, (1987) Monoclonal antibody DLC-48: an effective reagent for use in the depletion of malignant lymphoma from human bone marrow. Int J Cancer 39: 670-677.
16. Cooper N, Arnold DM, (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 149: 3-13.
17. Dorner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, et al. (2009) Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 9: 82-89.
18. Kessel A, Rosner I, Toubi E, (2008) Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 34: 74-79.
19. Buch T, Heppner FL, Tertilt C, Heinen TJ, Kremer M, et al. (2005) A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods 2: 419-426.
20. Waisman A, Croxford AL, Demircik F, (2008) New tools to study the role of B cells in cytomegalovirus infections. Med Microbiol Immunol 197: 145-149.
21. Rickert RC, Roes J, Rajewsky K, (1997) B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res 25: 1317-1318.
22. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, et al. (2001) Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 1: 4.
23. Cerny A, Starobinski M, Hugin AW, Sutter S, Zinkernagel RM, et al. (1987) Treatment with high doses of anti-IgM prevents, but with lower doses accelerates autoimmune disease in (NZW x BXSB)F1 hybrid mice. J Immunol 138: 4222-4228.
24. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, et al. (2006). B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169: 954-966.
25. Martinez-Gamboa L, Brezinschek HP, Burmester GR, Dorner T, (2006) Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun Rev 5: 437-442.
26. Waldor MK, Hardy RR, Hayakawa K, Steinman L, Herzenberg LA, (1984) Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies. Proc Natl Acad Sci U S A 81: 2855-2858.
27. Lehmann-Horn K, Schleich E, Hertzenberg D, Hapfelmeier A, Kumpfel T, et al. (2011) Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation 8: 146.
28. Ezeonyeji AN, Isenberg DA (2011) Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology (Oxford).
29. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, et al. (2008) Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180: 361-371.
30. Liu Q, Liu Z, Rozo CT, Hamed HA, Alem F, et al. (2007) The role of B cells in the development of CD4 effector T cells during a polarized Th2 immune response. J Immunol 179: 3821-3830.